Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shoshana Katz

Physician Assistant Fairfax, VA Physician Assistant

NPI 1114263613 CMS profile 10532927

3031 Javier Rd Ste 210, Fairfax, VA 22031

Open in the dashboard

General payments

$3,938

193 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shoshana Katz of Fairfax, VA is reported in the CMS Open Payments database as having received $3,938 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $684 34
2024 General $1,109 51
2023 General $1,078 52
2022 General $580 29
2021 General $487 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shoshana Katz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shoshana Katz were reported at $684. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shoshana Katz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $487 $132 $37–$438 $132
2022 $580 $155 $48–$522 $149
2023 $1,078 $167 $52–$557 $160
2024 $1,109 $178 $55–$600 $164
2025 $684 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Collegium Pharmaceutical, Inc. $971 47 payments
  2. AbbVie, Inc. $865 47 payments
  3. Electronic Waveform Lab, Inc. $342 18 payments
  4. Pfizer Inc. $227 9 payments
  5. Indivior Inc. $192 8 payments
  6. Scilex Pharmaceuticals Inc. $155 8 payments
  7. Lundbeck LLC $129 5 payments
  8. Nevro Corp. $91 3 payments
  9. Averitas Pharma Inc. $89 4 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $84 4 payments
  11. Other $793 40 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,938 193 payments
Products named General payments · program years 2021–2025
  1. XTAMPZA $605 30 payments
  2. UBRELVY $468 26 payments
  3. QULIPTA $372 22 payments
  4. BELBUCA $366 17 payments
  5. NURTEC ODT $227 9 payments
  6. ZAVZPRET $227 9 payments
  7. BOTOX $175 7 payments
  8. ZTLido $155 8 payments
  9. SUBLOCADE $152 6 payments
  10. VYEPTI $129 5 payments
  11. Other $1,338 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,610

Median for Physician Assistant: 241

Drug cost

$113,580

Median for Physician Assistant: $4,110

Branded share of claims

27.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 42 $23,883
Belbuca Buprenorphine Hcl Brand 25 $22,170
Oxymorphone Hcl Er Oxymorphone Hcl Brand 21 $10,441
Hydromorphone Er Hydromorphone Hcl Brand 20 $9,075
Movantik Naloxegol Oxalate Brand 22 $8,779
Oxycodone Hcl Generic 313 $6,280
Lidocaine Generic 46 $5,794
Buprenorphine Generic 16 $5,110
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 125 $3,164
Pregabalin Generic 107 $3,039

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $181
$181 42 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $139
$139 25 —
BOTOX
  • AbbVie, Inc. $109
$109 — —
QULIPTA
  • AbbVie, Inc. $97
$97 — —
UBRELVY
  • AbbVie, Inc. $90
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record